News und Analysen
Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics
Charles River Laboratories International, Inc. (NYSE: CRL) today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration with Axovia Therapeutics Ltd
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
Pfizer Inc. (NYSE: PFE) today announced positive top-line immunogenicity and safety data from the ongoing pivotal Phase 3 clinical trial (NCT05842967) MONeT (RSV IMmunizatiON Study for AdulTs at
Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of two abstracts for poster presentation at
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
Novocure (NASDAQ: NVCR) today announced 20 presentations on Tumor Treating Fields (TTFields) therapy will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2024, to
Agilent Brings Great Science to Life at Analytica 2024
Agilent Technologies Inc. (NYSE: A) today announced its participation in Analytica 2024, where it will unveil its latest innovations and transformative workflows. Analytica, the premier
U.S. FDA Renews DILIsym® Software Licenses for 7th Year
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that
Charles River to Perform Plasmid Production for Ship of Theseus
Charles River Laboratories International, Inc. (NYSE: CRL) and Ship of Theseus, a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, today announced a Good
Charles River to Perform Plasmid Production for Ship of Theseus
Charles River Laboratories International, Inc. (NYSE: CRL) and Ship of Theseus, a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, today announced a Good
STAAR Surgical Announces Preliminary Net Sales for First Quarter 2024
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on April 2, 2024, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement
Simulations Plus Reports Second Quarter Fiscal 2024 Financial Results
Simulations Plus, Inc. (NASDAQ: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial
Acadia Healthcare Announces Date for First Quarter 2024 Earnings Release
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its first quarter 2024 results on Wednesday, May 1, 2024, after the close of the market. Acadia will conduct a
Dexcom Publishes Annual Sustainability Report
DexCom, Inc. (NASDAQ:DXCM), the leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today released its annual Sustainability Report. This report provides updates on
Agilent at AACR 2024: Empowering Breakthroughs in Cancer Research and Diagnostics
Agilent Technologies Inc. (NYSE: A), a global leader in life sciences and diagnostics, announced today its participation in the American Association for Cancer Research Annual Meeting (AACR). At
Humana Healthy Horizons – Ohio partners with CPESN® USA to expand access to pharmacists
Humana Healthy Horizons, the Medicaid business of leading health and well-being company Humana, announced it is partnering with CPESN® USA in Ohio to expand access to pharmacists for its members
Acadia Healthcare Accelerates Access to Care With Uber Health
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced a collaboration with Uber Health (NYSE:UBER). The two companies are coming together to improve access to life-saving behavioral health
Agilent and UC San Diego Launch Center of Excellence in Cellular Intelligence
Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics, and applied chemical markets, and the University of California San Diego (UC San Diego), one of the top-ranked
Dexcom Schedules First Quarter 2024 Earnings Release and Conference Call for April 25, 2024 at 4:30 p.m. Eastern Time
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2024 financial results after market close on Thursday, April 25, 2024. Management will hold a conference call
Chemed To Report First-Quarter 2024 Earnings April 24, Related Conference Call To Be Held On April 25
Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the first quarter ended March 31, 2024, on Wednesday, April 24, 2024, following the close of trading on the
Charles River Laboratories Showcases Technology-Driven Capabilities at AACR 2024
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that its industry-leading team of oncology experts will attend the American Association for Cancer Research (AACR) Annual
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological
Agilent Launches New Advanced Dilution System to Increase Lab Efficiency
Agilent Technologies Inc. (NYSE: A) today announced the launch of the Advanced Dilution System, the ADS 2, a new automation workflow solution that will increase productivity, lower cost of
Novocure to Report First Quarter 2024 Financial Results
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2024 on Thursday, May 2, 2024, before the U.S. financial markets open. Novocure management will
Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 23rd Annual Needham Virtual Healthcare Conference on
Klinische Phase-3-Studie METIS erreicht primären Endpunkt und zeigt eine statistisch signifikante Verlängerung der Zeit bis zur intrakraniellen Progression bei Patient:innen mit Hirnmetastasen von nicht-kleinzelligem Lungenkrebs
Novocure (NASDAQ: NVCR) gab heute bekannt, dass die klinische Phase-3-Studie METIS ihren primären Endpunkt erreicht hat und eine statistisch signifikante Verbesserung der Zeit bis zur
